Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosa A Carrasco

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Biotechniques|May 27, 2003
One-step cellular caspase-3/7 assayRosa A Carrasco, Nancy B Stamm, Bharvin K R Patel
Molecular Cancer Therapeutics|January 11, 2011
Antisense inhibition of survivin expression as a cancer therapeuticRosa A Carrasco, Nancy B Stamm, Eric Marcusson, et al.
Molecular Cancer Therapeutics|February 17, 2016
A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor ResponseZhan Xiao, Rosa A Carrasco, Kevin Schifferli, et al.
Cancer Research|January 9, 2016
A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant TumorsHaihong Zhong, April Davis, Maria Ouzounova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2024
Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal CancersAllison M Barrett, Zachary T Britton, Rosa A Carrasco, et al.
The Journal of Clinical Investigation|November 15, 2023
Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancerPeter Zanvit, Dewald van Dyk, Christine Fazenbaker, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Biotechniques|May 27, 2003
One-step cellular caspase-3/7 assayRosa A Carrasco, Nancy B Stamm, Bharvin K R Patel
Molecular Cancer Therapeutics|January 11, 2011
Antisense inhibition of survivin expression as a cancer therapeuticRosa A Carrasco, Nancy B Stamm, Eric Marcusson, et al.
Molecular Cancer Therapeutics|February 17, 2016
A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor ResponseZhan Xiao, Rosa A Carrasco, Kevin Schifferli, et al.
Cancer Research|January 9, 2016
A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant TumorsHaihong Zhong, April Davis, Maria Ouzounova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2024
Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal CancersAllison M Barrett, Zachary T Britton, Rosa A Carrasco, et al.
The Journal of Clinical Investigation|November 15, 2023
Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancerPeter Zanvit, Dewald van Dyk, Christine Fazenbaker, et al.
Pageof 1